Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.